The comparative in vivo evaluation of [11C]erlotinib with the irreversible inhibitor [18F]afatinib has been recently described in mutation sensitized and wild-type EGFR-expressing tumor bearing mice [74]. The gene discussed is EGFR; the disease is neoplasm.